• Text Hover
  • Text Hover
The world's first bioabsorbable
magnesium alloy closure device.
Fast. Safe. Easy.

 

  • Text Hover

A first-of-its-kind magnesium alloy-based vascular closure device that offers a unique method of quickly achieving stable mechanical vascular closure following percutaneous catheterization for diagnostic or interventional procedures using 5-8 Fr procedural sheaths. The implant consists of a plug and footplate system that when presented to the arteriotomy, effects immediate, stable and reliable hemostasis.    Dr. Shing-Chiu Wong, Director of Cardiac Catheterization Laboratories at the New York Presbyterian — Weill Cornell Medical Center and a leading clinical participant in the velox CD™ clinical studies states, velox CD™ is the world’s first metal-based bioabsorbable closure device that is simple to use and highly predictable for femoral access site hemostasis. This innovation should prove to be a significant enhancement to the existing offerings.”

  • Text Hover
  • Text Hover
[vc_raw_html]JTNDaWZyYW1lJTIwc3JjJTNEJTIyaHR0cHMlM0ElMkYlMkZwbGF5ZXIudmltZW8uY29tJTJGdmlkZW8lMkYyMjA5ODc3MDAlMjIlMjB3aWR0aCUzRCUyMjY0MCUyMiUyMGhlaWdodCUzRCUyMjM2MCUyMiUyMGZyYW1lYm9yZGVyJTNEJTIyMCUyMiUyMHdlYmtpdGFsbG93ZnVsbHNjcmVlbiUyMG1vemFsbG93ZnVsbHNjcmVlbiUyMGFsbG93ZnVsbHNjcmVlbiUzRSUzQyUyRmlmcmFtZSUzRQ==[/vc_raw_html]
3 Easy Steps.

 
 



 

  • Text Hover
Preclinical Evidence.

Preclinical evidence demonstrates that the velox CD™ footplate absorbs in 24 hours and the plug within 2 weeks

  • Text Hover
Clinical Evidence.

velox CD™ Primary Safety & Efficacy End Points

Clinical Trials through May 2014

  • Text Hover
  • Text Hover

Fast. Safe. Easy.

Novel, minimally invasive cardiovascular devices.